D-070

N-Desmethylolanzapine-d₈ dihydrochloride solution

100 μg/mL in acetonitrile: water (1:1) (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 同義詞: N-Desmethylolanzapine-D₈ dihydrochloride solution
• 經驗公式（希爾表示法）: C₁₆D₈H₁₀N₄S · H₂Cl₂
• 分子量：: 379.38
• 分類程式碼代碼: 41116107
• NACRES: NA.24

屬性

• 等級: certified reference material
• 品質等級: 300
• 形狀: liquid
• 特點: Snap-N-Spike^®/Snap-N-Shoot^®
• 包裝: ampule of 1 mL
• 製造商／商標名: Cerilliant^®
• 濃度: 100 μg/mL in acetonitrile: water (1:1) (as free base)
• 技術: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• 應用: clinical testing
• 形式: single component solution
• 儲存溫度: 2-8°C

描述

一般說明

A stable-labeled internal standard for use in LC/MS or GC/MS applications including clinical toxicology analysis, therapeutic drug monitoring, or isotope dilution methods. Desmethylolanzapine is the primary metabolite of olanzapine, marketed as the atypical antipsychotic Zyprexa^® for the treatment of schizophrenia and bipolar disorder.

應用

• Monitoring Metabolic Parameters in Schizophrenia: A study utilized plasma levels of olanzapine and its metabolite, N-desmethyl-olanzapine, to monitor metabolic parameters in patients with schizophrenia, providing a critical link between antipsychotic drug concentrations and metabolic health. This research supports the use of these biomarkers in clinical settings to optimize therapeutic strategies and manage side effects (Lu et al., 2018).


• Evaluating Clinical Efficacy in Schizophrenia: Another significant study applied plasma levels of olanzapine and N-desmethyl-olanzapine to assess clinical efficacy in schizophrenia patients. By correlating drug levels with therapeutic outcomes, this approach aids in personalized medicine, ensuring patients receive optimal dosages for effective treatment (Lu et al., 2016).

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Zyprexa is a registered trademark of Eli Lilly and Co.

安全資訊

• 象形圖: GHS02,GHS07
• 訊號詞: Danger
• 危險聲明: H225,H302,H319
• 防範說明: P210 - P233 - P240 - P241 - P301 + P312 - P305 + P351 + P338
• 危險分類: Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
• 儲存類別代碼: 3 - Flammable liquids
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: 55.4 °F - closed cup
• 閃點（°C）: 13 °C - closed cup